Wigginton, J. M., Gruys, E., Geiselhart, L., Subleski, J., Komschlies, K. L., Park, J., . . . Wiltrout, R. H. (2001). IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. American Society for Clinical Investigation.
Citação norma ChicagoWigginton, Jon M., et al. IFN-γ and Fas/FasL Are Required for the Antitumor and Antiangiogenic Effects of IL-12/pulse IL-2 Therapy. American Society for Clinical Investigation, 2001.
Deismireacht MLAWigginton, Jon M., et al. IFN-γ and Fas/FasL Are Required for the Antitumor and Antiangiogenic Effects of IL-12/pulse IL-2 Therapy. American Society for Clinical Investigation, 2001.
Rabhadh: D'fhéadfadh nach mbeadh na deismireachtaí seo 100% cruinn i gcónaí.